Introduction {#Sec1}
============

On April 27, the number of confirmed worldwide SARS-CoV-2 infections has exceeded up to nearly 3 million cases and nearly 200,000 deaths \[[@CR1]\]. Consequently, increasing numbers of coronavirus disease (COVID-19) cases are expected to rapidly occur in people living with human immunodeficiency virus (PLWH). In the current COVID-19 pandemic, several comorbidities have been identified as risk factors for severe disease and death \[[@CR2]--[@CR5]\]. Data on PLWH are still scarce. A small case series from Spain recently described the clinical characteristics of five PLWH with COVID-19 \[[@CR6]\]. Coronaviruses such as severe acute respiratory syndrome (SARS)-CoV and SARS-CoV-2 have been shown to cause transient immune deficiency \[[@CR7]--[@CR9]\], indicating that HIV and COVID-19 may both carry deleterious immunological and clinical consequences. On the other hand, defective cellular immunity in PLWH could paradoxically be protective for severe cytokine dysregulation, which has been observed in patients with COVID-19. Moreover, some HIV protease inhibitors (PI) are thought to inhibit the 3-chymotrypsin-like protease of coronaviruses.

In this study, we describe our early experiences with COVID-19 and clinical characteristics in patients with documented HIV infection.

Methods {#Sec2}
=======

This retrospective analysis included all cases of PLWH with SARS-CoV-2 infection, which were confirmed between March 11 and April 17, 2020 in 12 participating German HIV centers. Anonymized data were collected by the treating physicians and included age, gender and HIV-associated parameters such as the last CD4+ T cells (absolute cells/mm^3^, as assessed by local labs), the last CD4/CD8 ratio, the last HIV-RNA (copies/mL, as assessed by local labs) and antiretroviral therapy before COVID-19 diagnosis. With regard to COVID-19, clinical symptoms, severity of disease classified as mild (i.e., non-pneumonia and mild pneumonia), severe (i.e., dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, and/or lung infiltrates \> 50% within 24--48 h), and critical (i.e., respiratory failure, septic shock, and/or multiple organ dysfunction or failure) \[[@CR10]\], and outcome were collected as well as comorbidities. Ethics committee approval was obtained from Technical University of Munich (April 4, 2020, Approval No. 194/20s).

Results {#Sec3}
=======

We identified 33 PLWH with confirmed SARS-CoV-2 infection. Positive SARS-CoV-2 PCR was obtained from nasopharyngeal swabs in 29, and from bronchoalveolar lavage or sputum in 2 cases; in two cases, no information about this was available. For 14 patients, a close contact to a person with SARS-CoV-2 infection has been documented. For seven patients, a travel history to foreign countries with a high transmission rate of SARS-CoV-2 has been reported. 26 patients were primarily diagnosed in the outpatient setting. In 7 patients, the diagnostic procedure was done in the hospitals during admission. Additionally, neither clusters of transmission nor nosocomial infections could be detected. Main characteristics are shown in Table [1](#Tab1){ref-type="table"}. Mean age was 48 years (range 26--82 years) and 30/33 patients were men. All patients were on antiretroviral therapy at the time of COVID-19 diagnosis. Antiretroviral regimens included nucleoside reverse transcriptase inhibitors (NRTIs) in 31, integrase strand transfer inhibitors (INSTI) in 20, protease inhibitors (PI) in 4 and Non-NRTIs in 9 cases. NRTIs were mainly tenofovir alafenamide (16 cases), tenofovir disoproxilfumarate (6 cases) and a cytidine analog, either emtricitabine (*n* = 22) or lamivudine (*n* = 9). The last median CD4+ T-cell count before SARS-CoV-2 infection was 670/mm^3^ (range 69--1715/mm^3^). In 30/32 cases, the last HIV-RNA was below 50 copies/mL. Two patients with detectable HI-viremia needed hospital admission including intensive care treatment and mechanical ventilation, and one of these patients died. Comorbidities other than HIV infection were documented in 20/33 (60%) patients, including arterial hypertension (*n* = 10), chronic obstructive pulmonary disease (*n* = 6), diabetes mellitus (*n* = 4), cardiovascular disease (*n* = 3) and renal insufficiency (*n* = 2). Coinfection with hepatitis B has been documented in five patients: a resolved hepatitis B (hepatitis B surface antigen negative) in four patients, and in one patient a chronic hepatitis B (hepatitis B envelope antigen positive). In one patient, a cured hepatitis C (sustained virologic response after 12 weeks of treatment with sofosbuvir/velpatasvir) has been reported.Table 1Patient characteristicsAge (years)SexYears since HIV diagnosisAntiretroviral treatment (ART)Years of ARTCD4 T-cell count per mm^3^CD4/CD8 ratioCD4 T-cell nadir (count per mm^3^)HIV-RNA (copies/mL)COVID-19 clinical classificationOutcome144M14DTG/ABC/3TC137540.83163 \< 50MildRecovered233F7RPV/TAF/FTC66190.9387 \< 50MildRecovered338M3BIC/TAF/FTC211871.52541 \< 50MildRecovered453M11NVP/ABC/3TC118100.53293 \< 50MildRecovered560M7DTG/TDF/FTC5.58921.00362 \< 50MildRecovered651M20DTG/3TC104020.4329 \< 50MildRecovered742M17DTG/ABC/3TC5.510870.9439 \< 50MildRecovered865M13BIC/TAF/FTC911220.93490 \< 50MildRecovered982M28DRV/RTV/RGV283790.4151920CriticalICU, NIV, death1053M10DRV/COBI/TAF/FTC0.52850.25204842CriticalICU, IV, discharged, recovered1132M10DRV/COBI/TAF/FTC107311.89325 \< 50MildRecovered1231M5EVG/COBI/TAF/FTC510001.15810 \< 50MildRecovered1337M10EVG/COBI/TAF/FTC89461.13580 \< 50MildRecovered1437F5DOR/TDF/FTC54020.5na \< 50SevereHospital, discharged, recovered1536M4DTG/ABC/3TC47181.2na \< 50CriticalICU, IV, discharged from ICU, Hospital1668M14DRV/COBI/TAF/FTC144990.9240 \< 50SevereHospital, discharged, recovered1742M11RPV/TDF/FTCna6131.3430 \< 50CriticalICU, discharged, recovered1835M3DTG/3TCna5381.0419 \< 50MildRecovered1955M10RPV/TAF/FTC107801.89370 \< 50MildRecovered2055M21BIC/TAF/FTC21690.068 \< 50CriticalICU, IV, death2158M16DTG145730.8314 \< 50MildRecovered2230M6DTG/ABC/3TC66081.00608 \< 50MildRecovered2326MnaBIC/TAF/FTCnananananaMildRecovered2459M15DOR/TDF/FTC157181.75230 \< 50CriticalICU, IV, death2531M7BIC/TAF/FTC56471.09390 \< 50MildRecovered2662M20NVP/TAF/FTC206924.94111 \< 50MildRecovered2753M6EVG/COBI/TAF/FTC67170.95457 \< 50MildRecovered2854M15BIC/TAF/FTC154370.68126 \< 50MildHospital, discharged, recovered2970M13NVP/TAF/FTC133360.38250 \< 50MildHospital, discharged, recovered3048M11DTG/3TC317150.91474 \< 50MildHospital, discharged, recovered3135M1RPV/TAF/FTC14900.55na \< 50MildHospital, discharged, recovered3245F5DTG/TDF/FTC52340.34150 \< 50MildHospital, discharged, recovered3366M31DTG/ABC/3TCna12501.76na \< 50MildHospital, discharged, recovered*ABC* abacavir, *BIC* bictegravir, *COBI* cobicistat, *DOR* doravirine, *DRV* darunavir, *DTG* dolutegravir, *EVG* elvitegravir, *F* female, *FTC* emtricitabine, *M* male, *NVP* nevirapine, *RAL* raltegravir, *RPV* rilpivirine, *RTV* ritonavir, *TAF* tenofovir alafenamide, *TDF* tenofovir disoproxil, *3TC* lamivudine, *ICU* intensive care unit, *IV* invasive ventilation, *NIV* non-invasive ventilation, *na* not available

The most common symptoms were cough in 25/32 (78%), fever in 22/32 (69%), arthralgia/myalgia 7/32 (22%), headache 7/32 (22%), and sore throat in 7/32 (22%). Sinusitis and anosmia occurred in 6/32 (19%) for each. At the last available follow-up, 29/32 of patients with documented outcome (91%) had recovered from COVID-19. Altogether, 14/33 (42%) patients were admitted to hospitals. Treatment on intensive care units (ICU) was necessary in 6 of 14 (43%) hospitalized patients. Of the 14 patients, requiring treatment in hospitals, 10 have been discharged in the meanwhile. One patient is still in hospital but discharged from ICU. In one patient, a spontaneous pneumothorax could be seen as a complication of persisting cough. Three out of 32 patients with documented outcome (9%) had died (patient \#9 aged 82 years, patient \#20 with a CD4+ T-cell count of 69/mm^3^ and a very low CD4/CD8 ratio of 0.06, and patient \#24 with several comorbidities as hypertension, chronic obstructive pulmonary disease, and diabetes mellitus type 2). The clinical case definition was mild in 25/33 cases (76%), severe in 2/33 cases (6%), and critical in 6/33 cases (18%).

Discussion {#Sec4}
==========

In the current COVID-19 pandemic, comorbidities such as arterial hypertension, cardiovascular disease, diabetes and cancer have been identified as risk factors for severe diseases \[[@CR2]--[@CR5]\]. However, as these cohort studies did not provide data on HIV infection, it remains unclear whether PLWH remain at higher risk for SARS-CoV-2 infection or at higher risk for severe courses. Previous studies on influenza viruses did not find an increased morbidity and mortality in PLWH \[[@CR11], [@CR12]\]. For SARS and COVID-19, a few case reports have indicated no severe courses even in AIDS patients \[[@CR13], [@CR14]\]. In the absence of controlled and/or larger data, a preliminary statement from the European AIDS Clinical Society explained that "there is no evidence for a higher COVID-19 infection rate or different disease course in people with HIV than in HIV-negative people" so far \[[@CR15]\].

In the present case series on 33 patients infected with symptomatic SARS-CoV-2 infection, 29/32 (91%) have recovered at the last follow-up and 76% have been classified as mild cases. However, 24% of the cases have been categorized as severe or critical cases. Three patients had died (9%). The following details provide some explanations: One patient was of older age (82 years) and had a detectable viral load before COVID-19. In the other deceased patient, only limited information was available but his last CD4 T-cell count and CD4/CD8 ratio were very low. The third patient suffered from several comorbidities as arterial hypertension, chronic pulmonary obstructive disease, and diabetes mellitus type 2. The case fatality rate of 9% is, therefore, higher than in the general population in Germany, where about 5640 patients of 154,175 confirmed COVID-19 cases died (3.7%) \[[@CR16]\]. Additionally, the number of severe and critical cases in our cohort (24%) seems to be somewhat higher than that reported from other cohorts (19%) \[[@CR10]\]. The hospitalization rate in our cohort was 42% and, therefore, higher than in the general population in Germany, where the hospitalization rate of COVID-19 patients is about 17% \[[@CR16]\]. Of the 14 hospitalized patients, 6/14 (43%) needed an admission to an intensive care unit. On the first look, this seems to be higher than it was reported in a large cohort in New York, where the ICU admission rate of patients with documented outcome was 14% \[[@CR17]\]. This could be due to involvement of two large university hospitals where only hospitalized patients were included. In addition, there might be an effect of higher hospitalization rates among patients with known HIV infection due to safety reasons. Nevertheless, the precise hospitalization rate among symptomatic cases is not known. In our cohort, only symptomatic patients were documented. In larger cohorts, it has been estimated that about 20--40% of SARS-CoV-2 infected people are asymptomatic \[[@CR18], [@CR19]\].

Therefore, it is very likely that we have overestimated total morbidity and mortality. Another aspect is the different mean age in large cohorts (63 years) \[[@CR17]\] and in our cohort. The mean age of 48 years in our cohort may correspond not only to the younger HIV infected population but also to the lower mean age of SARS-CoV-2 infected people in Germany of 50 years \[[@CR16]\]. The main symptoms reported in our cohort were mainly cough and fever. The clinical characteristics of COVID-19 did not appear to differ from those of the general population \[[@CR2], [@CR5], [@CR16]\].

All patients were on ART and all except four had CD4+ T-cells \> 350/mm^3^, indicating no severe immune deficiency. However, two patients with a detectable viremia required mechanical ventilation. Nevertheless, the data obtained did not reflect whether this was due to an insufficient antiretroviral treatment regimen, a treatment failure, or maybe due to the present COVID-19 disease. There are some data on immunological consequences from two retrospective studies of 21 and 44 HIV-negative patients with COVID-19, showing significant decreases of CD4+ T-cells in almost all patients, with a more pronounced decline in severe cases \[[@CR8], [@CR9]\]. There is also evidence from a larger study on SARS-CoV, showing a prolonged lymphopenia before returning towards normal after 5 weeks, with the lowest mean CD4+ T-cell count of 317 cells/µl \[[@CR7]\]. Up to now, it remains unclear whether this may translate into a higher risk for opportunistic infections.

We have identified 4/33 patients who acquired SARS-CoV-2, while these patients were treated with a PI containing regimen, consisting in boosted darunavir in all cases. This percentage does not appear to differ markedly from the total PLWH population in Germany, in which the proportion of patients on boosted PIs has constantly decreased during recent years \[[@CR20], [@CR21]\]. For another HIV-PI, lopinavir, uncontrolled studies have indicated a potential benefit in COVID-19 with early initiation \[[@CR22]--[@CR24]\]. In addition, a case--control study on Middle East Respiratory Syndrome (MERS) has suggested an effect for lopinavir/ritonavir as post-exposure prophylaxis in health care workers \[[@CR25]\]. However, the first randomized open-label trial in 199 adults with severe COVID-19 did not find any clinical or virological benefit with lopinavir/ritonavir beyond standard care \[[@CR26]\]. It was speculated that concentrations of protein-unbound lopinavir achieved by current HIV dosing are too low for inhibiting viral replication. Nevertheless, several trials of lopinavir and darunavir are ongoing, including a cluster-randomized clinical trial on 3.040 participants in Spain (HCQ4COV19). Our preliminary findings did not suggest a protective effect of darunavir which is in line with US Guidelines, recommending that ART regimen "should not be changed to include a PI to prevent or treat COVID-19, except in the context of a clinical trial and in consultation with an HIV specialist" \[[@CR27]\].

Besides PI, we did not find a clear evidence for a protective effect of tenofovir. Of note, the nucleoside analog remdesivir, which is currently tested in several clinical trials for COVID-19 \[[@CR28]\], has some chemical similarities to tenofovir alafenamide. In molecular docking studies, tenofovir has been recently shown to bind to SARS-CoV-2 RNA polymerase (RdRp) with binding energies comparable to those of native nucleotides und to a similar extent as remdesivir. Consequently, tenofovir has recently been suggested as a potential treatment for COVID-19 \[[@CR29]\]. In Spain, a large randomized phase 3 placebo-controlled study compares the use of tenofovir disoproxil fumarate/emtricitabine, hydroxychloroquine or the combination of both versus placebo as prophylaxis for COVID-19 in healthcare works \[[@CR30]\]. As the majority of our patients (22/33) was treated with tenofovir alafenamide or tenofovir disoproxil fumarate, including those developing severe or critical disease, our cohort data indicate no or only minimal clinical effect of tenofovir against SARS-CoV-2.

There is no doubt that our study has important limitations. First, this was a small retrospective and uncontrolled case series with limited follow-up. All patients were symptomatic, indicating that asymptomatic cases were probably missed. For the antiretroviral treatment regimen, we did not have the precise rates of overall PI or tenofovir prescriptions in the participating centers. Other important data were incomplete, including transmission and exposure conditions. In addition, detailed information about the onset, duration, intensity of the symptoms, and radiological details of CT scans were limited or not obtained in our retrospective analysis.

In conclusion, this preliminary case series does not support an excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART. Larger studies are needed to elucidate any protective or deleterious effect of HIV and antiretroviral therapy.
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